Category: Alexander Disease

The research behind the first FDA-approved drug for Alexander Disease

The FDA approved Zanvastro, the first drug to treat Alexander Disease, a breakthrough that wouldn’t have been possible without research at the Waisman Center. By Addison Dama for The Daily Cardinal October 8, 2026 | 2:00am CDT The Food and Drug Administration (FDA) approved Zanvastro, the first injectable treatment for Alexander Disease, on Sept. 3. …

First drug to treat Alexander disease approved by the FDA after three decades of research at UW–Madison

New research reveals parallels between Alexander disease and other neurodegenerative conditions like Alzheimer’s disease

New research from Waisman investigator, Tracy Hagemann, PhD, associate research professor, delves into the cognitive impairments and associated molecular changes caused by Alexander disease (AxD), revealing similarities to other neurodegenerative diseases like Alzheimer’s.

We need to know STAT: Mechanisms behind GFAP accumulation in Alexander disease involve transcription factor STAT3.

The hallmarks of Alexander disease, aggregation of misfolded GFAP proteins and dysregulation of brain cells called astrocytes, may be stopped and reversed in rodent models with the inactivation of the transcription factor STAT3.

Alexander disease: A lifetime’s work in the hope of saving lives

Messing wanted to study if the overexpression of GFAP resulted in a certain reactive response in the brain.

Two Waisman investigators named research professors

Two Waisman investigators were recently awarded a new professor title track at UW-Madison.

Promising treatment for Alexander disease moves from rat model to human clinical trials

Alexander disease is a progressive and rare neurological disorder with no cure or standard course of treatment. But a new study led by researchers at the University of Wisconsin–Madison involving a rat model of the disease offers a potential treatment for the typically fatal condition.

Waisman Center launches new fund to advance intellectual and developmental disabilities genomics research

The Waisman Center, University of Wisconsin-Madison, launched a new fund to support interdisciplinary research in the area of intellectual and developmental disabilities (IDD) genomics.

Mutation in common protein triggers tangles, chaos inside brain cells

In a study published today, Waisman Center investigators Su-Chun Zhang, Albee Messing and colleagues point to new understandings of the broad range of effects that result from the GFAP mutation impacting astrocytes — important supporting cells which comprise 20 to 40 percent of all cells in the brain. Cells donated by patients with Alexander disease …

Whirling the Waisman Way with Team Tristan

Picture a crisp October morning in Madison, Wisconsin – the bright colors of fall leaves, mists over the blue waters of Lake Mendota and – on one Sunday (the 14th this year) – a crowd of excited people waiting to run, walk or roll in the 2018 Waisman Whirl for ALL Abilities!